We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

COPAN ITALIA SPA

Copan is dedicated to developing high-quality sample collection products for infectious diseases, human genomics, env... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AST Automation System Rapidly Diagnoses Blood Stream Infection for Early Treatment Initiation

By LabMedica International staff writers
Posted on 12 May 2022
Print article
Image: Radian BC guarantees the shortest four hours incubation time for positive blood culture samples (Photo courtesy of Copan Group)
Image: Radian BC guarantees the shortest four hours incubation time for positive blood culture samples (Photo courtesy of Copan Group)

Every year, 30 million people worldwide get affected by a blood stream infection, pathologies often caused by antibiotic-resistant bacteria and characterized by up to 30% mortality. In these patients, reducing the time to diagnosis is not simply a good service, as the rapidity of appropriate treatment initiation may decrease their short-term mortality. Thus, any slight improvement in the complex and multitasked workflow that interposes between a blood sample collection and diagnosis can be life-saving. Now, a new antimicrobial susceptibility testing (AST) automation system guarantees the shortest four hours incubation time for positive blood culture samples, thereby reducing the incubation time for blood stream infection patients to allow for early intervention with a targeted antimicrobial therapy.

Copan Group’s (Brescia, Italy) Radian is an integrated module of the company’s full lab automation ecosystem that already eases the AST tasks of healthcare professionals by automating antibiotic disks application on WASPLab streaked plates, followed by automated incubation, digital imaging, and interpretation to derive antibiotic susceptibility results. Disk diffusion is the only antibiotic susceptibility testing that provides a true image of bacterial growth, enabling microbiologists to detect culture purity, heterogeneous growth or colony morphology, as well as antibiotic interactions, to adapt antimicrobial treatment more rapidly.​ With Radian, automation gets rid of the disadvantages linked to manual disk diffusion while maintaining at the same time its original advantages.

Copan has now pushed Radian even further to develop Radian BC. Integrating EUCAST Rapid AST Rules (R-AST) into the automated workflow, Radian BC is the first platform to provide accurate therapy indications for blood stream infection patients with just a four hour incubation period. Like no other AST automation available today, Radian BC guarantees the shortest four hours incubation time for positive blood culture samples. By reducing the incubation time for blood stream infection patients to a quarter, Radian BC ensures to specialists unparalleled rapid diagnostic assessment, directing each patient towards an early intervention with a targeted antimicrobial therapy.

Related Links:
Copan Group 

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
New
Specimen Radiography System
XPERT 80
New
Gold Supplier
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.